Search - tctmd.com

Displaying 21 - 40 of 51

Sort: Relevancy | Date

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

L.A. McKeown

April 02, 2020

Presentation ACC 2020

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

Presenter: William Hiatt

March 29, 2020

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

L.A. McKeown

March 28, 2020

News Daily News

Outcome Differences Between Men and Women With PAD: EUCLID Insights

L.A. McKeown

February 11, 2020

News Daily News

Bleeding Risk Similar for Peripheral, Coronary Revascularization: EUCLID

Caitlin E. Cox

October 16, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Yael L. Maxwell

June 08, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for January 2018

Shelley Wood

January 31, 2018

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

L.A. McKeown

January 02, 2018

News Daily News

The Biggest News of 2017: TCTMD’s Top 10

Shelley Wood

January 01, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

Shelley Wood

September 30, 2017

News Opinion Editor's Corner ESC 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

Shelley Wood

September 08, 2017

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

Presentation

Association Between CKD and Outcomes With Use of Prasugrel vs Clopidogrel in PCI for ACS

August 04, 2017

News Daily News

Two New Trials Buoy Outlook for PFO Closure in Patients With Cryptogenic Stroke

Todd Neale

May 24, 2017

News Conference News AHA 2016

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Yael L. Maxwell

November 13, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Daily News

EUCLID: Ticagrelor Holds No Edge Over Clopidogrel for Preventing Atherothrombotic Events in Symptomatic PAD Patients

Shelley Wood

October 07, 2016

News Daily News

Ensayo EUCLID: Ticagrelor No es Más Beneficioso que Clopidogrel en la Prevención de Episodios CV en Pacientes con EAP Sintomática

Shelley Wood

October 07, 2016

News Conference News ESC 2016

Valve Thrombosis After TAVR Linked to Larger Device Size, Lack of Warfarin Therapy

Todd Neale

September 02, 2016

Advertisement

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

Outcome Differences Between Men and Women With PAD: EUCLID Insights

Bleeding Risk Similar for Peripheral, Coronary Revascularization: EUCLID

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

TCTMD’s Top 10 Most Popular Stories for January 2018

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

The Biggest News of 2017: TCTMD’s Top 10

TCTMD’s Top 10 Most Popular Stories for September 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Association Between CKD and Outcomes With Use of Prasugrel vs Clopidogrel in PCI for ACS

Two New Trials Buoy Outlook for PFO Closure in Patients With Cryptogenic Stroke

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

EUCLID: Ticagrelor Holds No Edge Over Clopidogrel for Preventing Atherothrombotic Events in Symptomatic PAD Patients

Ensayo EUCLID: Ticagrelor No es Más Beneficioso que Clopidogrel en la Prevención de Episodios CV en Pacientes con EAP Sintomática

Valve Thrombosis After TAVR Linked to Larger Device Size, Lack of Warfarin Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content